News

“We all know that exacerbations are the most costly disease impact of COPD,” study investigator Dr. Charlie Strange says.

The approval makes odevixibat the second IBAT inhibitor approved for the rare genetic disease, with capability to benefit both liver damage and itch symptoms.

At the 7th Annual Heart in Diabetes meeting, Joseph discussed the need to advance equity in diabetes management, from clinical practice to community-based interventions.

An investigator argues for greater prescriber understanding and communication of real-world efficacy and safety outcomes for the latest oral JAK inhibitor approved for atopic dermatitis.

In this Q&A interview, Dr. Glick delved into the topics covered in his conference presentation on treating adults with plaque psoriasis and psoriatic arthritis.

Patients with autoimmune hepatitis who were positive for antimitochondrial antibodies and evidence of non-specific bile duct injury had a higher risk of progressing to cirrhosis.

Oral JAK-1 inhibitors upadacitinib and povorcitinib are showing significant benefit for patients with HS, and may soon be up for FDA decision.

Stephen Greene, MD, discusses the results of a recent GWTG-HF registry analysis, which concluded just 1 in 5 hospitalized patients with HFrEF were discharged with an SGLT2 inhibitor prescription and less than 10% were receiving all 4 classes of guideline-directed medical therapy.

This data indicates that to prevent aggravation of acne and the eventual scar formation, it may be necessary to treat acne from an early stage.

An analysis suggests biosimilar bevacizumab was safe and effective over 6 weeks with noted improvement in BCVA and OCT parameters for patients with macular edema.

After rituximab treatment, patients experienced a reduction of symptoms, corticosteroid administration, and median corticosteroid dose from baseline.

These positive outcomes are promising for individuals struggling with narcolepsy, as they provide hope for improved management of their condition. However, Harsh says oxybate therapy is not for everyone.

Cross-sectional findings from Hong Kong suggest exposure to secondhand smoke presented a dose-dependent association with myopia among children aged 6 to 8 years.

In this Q&A interview, Del Rosso discussed his presentation on eczema therapies, the updates he made to his conference presentations this year, as well as his outlook on future research.

The next step for investigating sodium oxybate is to examine the safety and efficacy with other sleeping populations, primarily, hypersomnia.

The treatment represents the first approval for pediatric patients with functional constipation.

Steve Greene, MD, discusses the results of a TRANSFORM-HF analysis comparing the effects of furosemide and torsemide on quality of life outcomes in patients with heart failure.

After they adjusted for manufacturer rebates to estimate net prices, the investigators fund HCV drug prices decreased by 31% from 2013-2020.

This interview with Dr. Bhatia featured a discussion about his views on newer therapies for dermatologic conditions as well as his outlook on the current research landscape.

Our latest cardiology case report from Brady Pregerson, MD, features a man in his mid-60s presenting with chest pains and palpitations. Can you determine the correct diganosis?

In this segment of her interview, Hebert went further in depth about the main points covered in her conference talk regarding new developments in pediatric dermatology.

This interview featured a discussion with Dr. Hebert in which she addressed the biggest takeaways of her conference presentation titled ‘What’s New in Pediatric Dermatology.’

This interview segment featured Dr. Alexis describing his views on the ways in which the dermatology field may be able to better address disparities in care for those with skin of color.

Cases have increased annually; a clinician shares his strategy for remaining aggressive and diligent in prevention and management.

In this interview, Dr. Alexis spoke about the ways in which the dermatology field should address the needs of patients with skin of color.

In this segment, Dr. Del Rosso discussed a conference presentation he gave titled ‘What You Really Need to Know About Rosacea.’

Secukinumab and bimekizumab may reach the market soon for the treatment of HS. What will it provide patients?

In this interview, Dr. Bhatia described the main takeaways from his conference presentation titled ‘JAKs and TYKs - What you Need to Know.’